Vanguard Capital Management
SUPN icon

Vanguard Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Vanguard Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117M Buy
2,516,721
+49,506
+2% +$2.38M ﹤0.01% 1477
2026
Q1 		$128M Buy
+2,467,215
New +$126M ﹤0.01% 1337

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management's SUPN Position: Q2 2026 in Review

Vanguard Capital Management increased its Supernus Pharmaceuticals (SUPN) stake by 2% in Q2 2026, buying an estimated $2.38M and bringing the position to 2,516,721 shares worth $117M. The position accounts for ﹤0.01% of the portfolio, ranked #1477.

Vanguard Capital Management first reported a position in SUPN in Q1 2026 and has held it in 2 quarters since. The position peaked at $128M in Q1 2026. 330 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Vanguard Capital Management held 2,516,721 shares of Supernus Pharmaceuticals worth $117M as of Q2 2026.
  • Vanguard Capital Management bought 49,506 Supernus Pharmaceuticals shares in Q2 2026, an estimated $2.38M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1477 holding.
  • Vanguard Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Supernus Pharmaceuticals position peaked at $128M in Q1 2026.
  • 330 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.